- Home
- DKNG vs MDGL Comparison
DKNG vs MDGL Comparison
Compare DKNG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DKNG | MDGL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 12.0B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DKNG | MDGL |
|---|---|---|
| Price | $23.66 | $517.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 30 | 12 |
| Target Price | $39.66 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 12.9M | 355.0K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.05 | 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,054,525,000.00 | $180,133,000.00 |
| Revenue This Year | $15.50 | $58.39 |
| Revenue Next Year | $13.07 | $47.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.99 | N/A |
| 52 Week Low | $20.46 | $265.00 |
| 52 Week High | $48.78 | $615.00 |
Technical Indicators
Market Signals| Indicator | DKNG | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 58.14 |
| Support Level | $20.74 | $503.93 |
| Resistance Level | $24.05 | $610.00 |
| Average True Range (ATR) | 0.87 | 27.19 |
| MACD | 0.22 | 0.46 |
| Stochastic Oscillator | 89.69 | 52.89 |
Price Performance
Historical ComparisonAbout DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. DraftKings is now live with online or retail sports betting in 28 states and i-gaming in 5 states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company plans to launch a predictive event platform in late 2025 and also operates a non-fungible token commission-based marketplace and develops and licenses online gaming products.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.